
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : AKE-1018
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Weill Cornell Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Akelos Inc.'s Lead Compound Achieves Preclinical Safety Milestone
Details : Akelos's oral lead compound AKE-1018, at 10-times the lowest effective antihyperalgesic dose tested, does not affect heart rate, blood pressure, motor strength/coordination, is non-sedating, and lacks the potential for abuse.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 04, 2021
Lead Product(s) : AKE-1018
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Weill Cornell Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
